AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$XGN

ABALLI JOHN sold $270K of XGN

ABALLI JOHN (President and CEO) sold 34,294 shares of EXAGEN INC. (XGN) at $7.87 ($0.27M total) on 2026-10-16.

Original reporting
SEC EDGAR · ABALLI JOHN
Published Oct 19, 2026, 8:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$XGN
Bearish
medium confidence
Mentioned
$XGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XGNBearishLow
01

Why it matters

Provides fresh, primary data on insider activity for Exagen Inc.

02

Market read

Insider sales are monitored for sentiment; this modest sale may cause slight pressure.

03

What to watch

The CEO retains a large stake (over 800k shares), suggesting continued confidence.

Relevance 4/10Novelty 4/10Timing: post-market filing on Oct 19

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$XGNBearishMedium confidence
Context

CEO John Aballi sold 34,294 shares for $269,791, reducing his stake to 805,540 shares.

Expected impact

likely modest downward pressure as the market prices in the insider sell

Evidence & confidence

Insider sales by a CEO are closely watched; although the amount is modest, it can influence sentiment.

Market effects

Sector

Minimal impact on the broader biotech sector; the sale is company-specific.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be routine diversification and not indicative of future performance.

Key entities

  • Company
    Exagen Inc.

    Biotech firm listed on NASDAQ under ticker XGN.

  • Executive
    John Aballi

    President and CEO of Exagen Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

XGN insider trading history →

Related articles

$XGNLow

Exagen Inc. Reports Third Quarter 2026 Financial Results

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Third Quarter 2026 Financial Results Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% November 10, 2026 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a precisio

SEC EDGAR 8-K
$XGNMedAI 8/10

Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance

Exagen (NASDAQ:XGN) reported record Q2 2026 revenue of $19.9 million, up 16% year over year, driven by an 11% rise in AVISE CTD testing volume and a 4% higher trailing twelve-month average selling price to $446 per test. Adjusted EBITDA loss narrowed to $0.1 million. Exagen raised full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million.

yahoo.com
$XGNMedAI 8/10

Exagen Inc. Q2 2026 Earnings Call Summary

Exagen Inc. reported record Q2 2026 revenue of $19.9 million, up 16% year over year, helped by record AVISE test volumes and higher trailing 12-month ASP near $446. The company raised full-year 2026 revenue guidance to $72 million to $75 million and expects adjusted EBITDA breakeven around $80 million of revenue. Exagen also discussed collections, reimbursement timing, and a myositis product launch in early 2027.

yahoo.com
$XGNMed

Exagen Inc. Reports Second Quarter 2026 Financial Results

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Second Quarter 2026 Financial Results Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million August 4,

SEC EDGAR 8-K